RxDoctor Payments Data

Nicholas Fleming, MD

Neurology · Charlotte, NCNPI 1528455888

Payments from drug & device makers

$41,327in general payments, 2019–2025

Across 23 payments — averaging $1796.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$21K
  • Medtronic$20K
  • Acadia Pharmaceuticals Inc$126
  • Teva Pharmaceuticals USA, Inc.$111
  • Eton Pharmaceuticals, Inc.$20
  • AbbVie$17
  • plus $16 from 1 others

What the payments were for

  • Grants$38,75094%
  • Travel & lodging$1,9175%
  • Food & beverage$4791%
  • Education$1810%

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific7$21,029
Medtronic10$20,007
Acadia Pharmaceuticals Inc2$126
Teva Pharmaceuticals USA, Inc.1$111
Eton Pharmaceuticals, Inc.1$20
AbbVie1$17
Sunovion Pharmaceuticals Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,327 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$182,333
Medicare patients
501
Services billed
10,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate125$966,829
NuplazidPimavanserin Tartrate60$290,549
AustedoDeutetrabenazine20$162,709
GocovriAmantadine Hcl21$82,692
RytaryCarbidopa/Levodopa34$50,740
Carbidopa-LevodopaCarbidopa/Levodopa1,203$46,376
Tetrabenazine24$37,878
Carbidopa-Levodopa ErCarbidopa/Levodopa252$9,835
Entacapone49$8,644
Rasagiline Mesylate52$5,538
Primidone177$4,519
AmantadineAmantadine Hcl61$3,911
Pramipexole DihydrochloridePramipexole Di-Hcl77$2,233
Pyridostigmine Bromide19$2,211
Fludrocortisone Acetate38$1,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$126$290,54960 claims
Teva Pharmaceuticals USA, Inc.Austedo$111$162,70920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 566 neurology providers in North Carolina.

Other neurology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →